Engineered human hepatocyte organoids enable CRISPR-based target discovery and drug screening for steatosis

The lack of registered drugs for nonalcoholic fatty liver disease (NAFLD) is partly due to the paucity of human-relevant models for target discovery and compound screening. Here we use human fetal hepatocyte organoids to model the first stage of NAFLD, steatosis, representing three different trigger...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendriks, Delilah, Brouwers, Jos F., Hamer, Karien, Geurts, Maarten H., Luciana, Léa, Massalini, Simone, López-Iglesias, Carmen, Peters, Peter J., Rodríguez-Colman, Maria J., Chuva de Sousa Lopes, Susana, Artegiani, Benedetta, Clevers, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635827/
https://www.ncbi.nlm.nih.gov/pubmed/36823355
http://dx.doi.org/10.1038/s41587-023-01680-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635827/
https://www.ncbi.nlm.nih.gov/pubmed/36823355
http://dx.doi.org/10.1038/s41587-023-01680-4

Ejemplares similares